A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia
NCT ID: NCT01490567
Last Updated: 2011-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2011-06-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
Subjects will be given with a dose of 5mg/day placebo. All drugs will be administered orally.
placebo
placebo 5mg/d
donepezil
Subjects will be given with a dose of 5 mg/day donepezil. All drugs will be administered orally.
Donepezil
5 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Donepezil
5 mg/day
placebo
placebo 5mg/d
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between 18 and 40 years of age;
* Duration of the illness must be longer than 2 year;
* Patient's current antipsychotic medication regimen must be stable;
* Must be in a stable living arrangement;
Exclusion Criteria
* Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening;
* Has suicidal attempts or ideation or violent behavior within the last 12 months;
* Patient has a history of alcohol/drug dependence;
18 Years
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xiaofeng Guo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaofeng Guo, doctor
Role: PRINCIPAL_INVESTIGATOR
Second Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaofeng Guo, Doctor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201002003
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
NSFC30900485
Identifier Type: -
Identifier Source: org_study_id